Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall aims of this study are to compare the structure and function of dry to very dry and cracked foot skin between diabetic and nondiabetic subjects and to evaluate the effects of two cosmetic leave-on products on dry and fissured diabetic foot skin.
Specific issues are:
Are there any differences between the morphological and functional characteristics of dry to very dry and cracked skin foot between diabetic and nondiabetic subjects? What are the effects of a 4-week once daily application of an intensive care foot ointment (urea 10% foot ointment) or foot lotion (10% Urea foot lotion) on the skin barrier and on clinical signs of dryness and fissures?
A long existing diabetes mellitus type II is often associated with a number of skin changes. Xerosis Cutis is the most common skin alteration. The risk of diabetics of developing a foot ulcer is estimated to be 15%. Very dry and cracked skin represents an additional risk factor, so that adequate skin care is a widely recommended intervention in diabetic patients. But there are only few studies investigating the skin barrier structure and function in diabetic patients. Available study results seem to suggest, that for instance sebum content, stratum corneum hydration, and pH are associated with Diabetes mellitus.
The overall aims of this study are to compare the structure and function of dry to very dry and cracked foot skin between diabetic and nondiabetic subjects and to evaluate the effects of two cosmetic leave-on products on dry and fissured diabetic foot skin.
Specific issues are:
Are there any differences between the morphological and functional characteristics of dry to very dry and cracked skin foot between diabetic and nondiabetic subjects? What are the effects of a 4-week once daily application of an intensive care foot ointment (urea 10% foot ointment) or foot lotion (10% Urea foot lotion) on the skin barrier and on clinical signs of dryness and fissures?
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| non diabetic | No Intervention | Control Group of 20 non-diabetics. Skin measurements, evaluation of skin dryness and sampling of skin particles will be performed | |
| moderate dryness-diabetic | Experimental | Experimental: Diabetics with moderate dryness. Intervention Group of 20 diabetics with moderate dryness 10% Urea foot lotion During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser "Cetaphil® Restoraderm Body Wash" and apply the product "Excipial® U10 Lipolotion 10% Urea" once daily in the evening by themselves. |
|
| severe dryness- diabetic | Experimental | Intervention Group of 20 diabetics with severe dryness 10% Urea foot ointment During the course of the study participants cleanse their feet once daily using the mild cleanser "Cetaphil® Restoraderm Body Wash" and apply the product "Excipial® Fuss Salbe 10% Urea" on both feet once daily in the evening by themselves. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 10% Urea foot lotion | Other | During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser "Cetaphil® Restoraderm Body Wash" and apply the product "Excipial® U10 Lipolotion 10% Urea" once daily in the evening by themselves. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in Overall Dry Skin Score | Clinical assessment of the presence or severity of skin dryness using a 7 point scale at the sole of the foot (randomized). A score of '0' indicated normal skin/no sign of dryness, whereas a score of '6' indicates large-scale plates, deep erythematous fissures and cracks | Baseline; Day 28±2 |
| Measure | Description | Time Frame |
|---|---|---|
| Skin barrier | Transepidermal water loss: Measurement using the Tewameter® Three replicate measurements; according to the Technical Procedures G01_A1_V01 g/m2/h | Day 0, Day 14±1,Day 28±2 |
| Measure | Description | Time Frame |
|---|---|---|
| Stratum corneum hydration | Stratum corneum hydration - Measurement using the Corneometer at Day 28 | Day 28 |
| Skin surface pH | Skin surface pH Measurement using the pH-Meter® Three replicate measurements; according to the Technical Procedures G01_A4_V01 |
diabetics and non-diabetics
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ulrike Blume -Peytavi, Prof Dr.med | Charité Universitatsmedizin Berlin | Principal Investigator |
| Ulrike Blume-Peytavi, Prof Dr.med | Charité Universitatsmedizin Berlin | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Charité Universitatsmedizin Berlin | Berlin | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Single Blind (Investigator) Non-Randomized 60 [Anticipated]
Not provided
Not provided
Not provided
|
| 10% Urea foot ointment | Other | During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser "Cetaphil® Restoraderm Body Wash" and apply the product "Excipial® U10 ointment10% Urea" once daily in the evening by themselves. |
|
| Day 0 , Day 14, Day 28 |
| Epidermal thickness | Epidermal thickness Measurement using OCT taking one image/ visit/ test area Mean of three epidermal thickness measurements; according to the Technical Procedures G04_A1_V01 μm | D28 |
| Skin surface topography | Skin surface topography - Measurement using Visioscan® | Day 0, Day 28±2 |
| Elasticity/Stiffness | Elasticity/Stiffness Measurement using Cutometer® at day 28 | Day 28 |
| lipids | Oxidative stress on lipids Measurement according to sampling method of Synelvia (Version 2) | Day 0, Day 28 |
| Callus | Callus
| Day 0, Day 28 |
| Cracks/ Fissures | Cracks/ Fissures
| Day 0, Day 28 |
| D004700 | Endocrine System Diseases |